Invention Grant
- Patent Title: Anti-PD-L1 combinations for treating tumors
-
Application No.: US16029352Application Date: 2018-07-06
-
Publication No.: US11279761B2Publication Date: 2022-03-22
- Inventor: Lixin Li
- Applicant: BIRDIE BIOPHARMACEUTICALS, INC.
- Applicant Address: KY Grand Cayman
- Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
- Current Assignee: BIRDIE BIOPHARMACEUTICALS, INC.
- Current Assignee Address: KY Grand Cayman
- Agency: K&L Gates
- Agent Louis C. Cullman; Benjamin D. Heuberger
- Priority: CN201410325480.9 20140709,CN201410440824.0 20140901
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K31/395 ; A61K31/4375 ; A61K31/4745 ; A61K31/708 ; A61K45/06 ; A61K31/4985 ; A61K31/519 ; A61K31/52 ; A61K31/522 ; A61K31/55 ; A61K31/5513 ; A61K31/7064 ; A61P35/00 ; C07K16/30 ; A61K39/00
Abstract:
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.
Public/Granted literature
- US20180346572A1 ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS Public/Granted day:2018-12-06
Information query
